http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 30 Jun 2025 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+27/24994591.html si-local-file:///var/storage/secattach/20250630/24994591.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+27/24994591.html Mon, 30 Jun 2025 08:00:00 -0400 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+27/24994591.html si-local-file:///var/storage/secattach/20250630/24994591.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+27/24994591.html Mon, 30 Jun 2025 08:00:00 -0400 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+18/24959384.html si-local-file:///var/storage/secattach/20250620/24959384.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+18/24959384.html Fri, 20 Jun 2025 16:10:00 -0400 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+18/24959384.html si-local-file:///var/storage/secattach/20250620/24959384.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+Jun+18/24959384.html Fri, 20 Jun 2025 16:10:00 -0400 O.26574658 UBX http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24849750.html <p>H.C. Wainwright analyst Andrew Fein downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Buy to Neutral with a price target of $2.00.</p><p>The analyst comments "Management transitions and platform direction forthcoming. In light of: (1) the recent management changes including transition of the roles of CEO, CFO, and Chief Legal Officer moving into consulting roles as the company evaluates strategic alternatives; and (2) the previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema (DME) patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis, we have revised our http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24849750.html Tue, 27 May 2025 06:06:39 -0400 UBX http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24849750.html <p>H.C. Wainwright analyst Andrew Fein downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Buy to Neutral with a price target of $2.00.</p><p>The analyst comments "Management transitions and platform direction forthcoming. In light of: (1) the recent management changes including transition of the roles of CEO, CFO, and Chief Legal Officer moving into consulting roles as the company evaluates strategic alternatives; and (2) the previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema (DME) patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis, we have revised our http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24849750.html Tue, 27 May 2025 06:06:39 -0400 UBX http://www.streetinsider.com/Downgrades/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24818357.html <p>Mizuho analyst Salim Syed downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Outperform to Neutral with a price target of $1.00 (from $6.00).</p> <p>For an analyst ratings summary and ratings history on Unity Biotechnology Inc <a href="http://www.streetinsider.com/rating_history.php?q=UBX">click here</a>. For more ratings news on Unity Biotechnology Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=UBX&amp;type=analyst">click here</a>.</p> <p>Shares of Unity Biotechnology Inc closed at $0.82 yesterday.</p> http://www.streetinsider.com/Downgrades/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24818357.html Mon, 19 May 2025 06:39:41 -0400 UBX http://www.streetinsider.com/Analyst+PT+Change/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24818357.html <p>Mizuho analyst Salim Syed downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Outperform to Neutral with a price target of $1.00 (from $6.00).</p> <p>For an analyst ratings summary and ratings history on Unity Biotechnology Inc <a href="http://www.streetinsider.com/rating_history.php?q=UBX">click here</a>. For more ratings news on Unity Biotechnology Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=UBX&amp;type=analyst">click here</a>.</p> <p>Shares of Unity Biotechnology Inc closed at $0.82 yesterday.</p> http://www.streetinsider.com/Analyst+PT+Change/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24818357.html Mon, 19 May 2025 06:39:41 -0400 UBX http://www.streetinsider.com/Downgrades/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html <p>Mizuho analyst Salim Syed downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Outperform to Neutral with a price target of $1.00 (from $6.00).</p><p>The analyst comments "UBX (Downgrading to N from OP, lowering PT to $1 from $6): Lowering our PT to $1 from $6. The key change to our model is lowering the PoS for UBX1325 on technical trial failure. We still believe the molecule has potential (our note here), and full 36-week data looks decent, but a strategic partner is now needed to continue its development, and it will take some time for this story to iron itself out. We http://www.streetinsider.com/Downgrades/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html Fri, 16 May 2025 09:09:16 -0400 UBX http://www.streetinsider.com/Analyst+PT+Change/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html <p>Mizuho analyst Salim Syed downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Outperform to Neutral with a price target of $1.00 (from $6.00).</p><p>The analyst comments "UBX (Downgrading to N from OP, lowering PT to $1 from $6): Lowering our PT to $1 from $6. The key change to our model is lowering the PoS for UBX1325 on technical trial failure. We still believe the molecule has potential (our note here), and full 36-week data looks decent, but a strategic partner is now needed to continue its development, and it will take some time for this story to iron itself out. We http://www.streetinsider.com/Analyst+PT+Change/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html Fri, 16 May 2025 09:09:16 -0400 UBX http://www.streetinsider.com/Analyst+Comments/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html <p>Mizuho analyst Salim Syed downgraded Unity Biotechnology Inc (NASDAQ: UBX) from Outperform to Neutral with a price target of $1.00 (from $6.00).</p><p>The analyst comments "UBX (Downgrading to N from OP, lowering PT to $1 from $6): Lowering our PT to $1 from $6. The key change to our model is lowering the PoS for UBX1325 on technical trial failure. We still believe the molecule has potential (our note here), and full 36-week data looks decent, but a strategic partner is now needed to continue its development, and it will take some time for this story to iron itself out. We http://www.streetinsider.com/Analyst+Comments/Mizuho+Downgrades+Unity+Biotechnology+Inc+%28UBX%29+to+Neutral/24812980.html Fri, 16 May 2025 09:09:16 -0400 UBX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unity+Biotechnology%2C+++++++++++++++++++Filed+by%3A+Alyeska+Investment+Group%2C+L.P./24809253.html si-local-file:///var/storage/secattach/20250515/24809253.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unity+Biotechnology%2C+++++++++++++++++++Filed+by%3A+Alyeska+Investment+Group%2C+L.P./24809253.html Thu, 15 May 2025 16:35:00 -0400 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unity+Biotechnology%2C+++++++++++++++++++Filed+by%3A+Alyeska+Investment+Group%2C+L.P./24809253.html si-local-file:///var/storage/secattach/20250515/24809253.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Unity+Biotechnology%2C+++++++++++++++++++Filed+by%3A+Alyeska+Investment+Group%2C+L.P./24809253.html Thu, 15 May 2025 16:35:00 -0400 O.26574658 UBX http://www.streetinsider.com/Corporate+News/UNITY+Biotechnology+%28UBX%29+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325/24739113.html <p>UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The Company previously disclosed 24-week and interim 36-week <span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=diu3sRtqDoO3CddHHbn-1YIMcDhLulLaVJA8eviOj85ECqub7JGw6zYVthGHGN5dU1NfRG3nappEVwgUj97ZXPYxytFSZ6q5Knqo6QgGuFhtRzj1FjjvaTh8dVzlXEJEj_k2kAiqsuewPlBupiFb-57G6-mr_p2ShyKM1ta3lIZRjAmQ1VxbkKhKbTKVEKyOlv3t-JxfijwSdE745k9nJO0ELZZwbQPIxWDCfKIidMg=" rel="nofollow">results</span> from its ASPIRE trial, demonstrating that UBX1325 was non-inferior to aflibercept at most time points through 36 weeks, except for the average of weeks 20 and 24, the primary endpoint.</p><p><strong>Phase 2b ASPIRE study results from all subjects through http://www.streetinsider.com/Corporate+News/UNITY+Biotechnology+%28UBX%29+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325/24739113.html Mon, 05 May 2025 08:01:55 -0400 UBX http://www.streetinsider.com/FDA/UNITY+Biotechnology+%28UBX%29+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325/24739113.html <p>UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The Company previously disclosed 24-week and interim 36-week <span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=diu3sRtqDoO3CddHHbn-1YIMcDhLulLaVJA8eviOj85ECqub7JGw6zYVthGHGN5dU1NfRG3nappEVwgUj97ZXPYxytFSZ6q5Knqo6QgGuFhtRzj1FjjvaTh8dVzlXEJEj_k2kAiqsuewPlBupiFb-57G6-mr_p2ShyKM1ta3lIZRjAmQ1VxbkKhKbTKVEKyOlv3t-JxfijwSdE745k9nJO0ELZZwbQPIxWDCfKIidMg=" rel="nofollow">results</span> from its ASPIRE trial, demonstrating that UBX1325 was non-inferior to aflibercept at most time points through 36 weeks, except for the average of weeks 20 and 24, the primary endpoint.</p><p><strong>Phase 2b ASPIRE study results from all subjects through http://www.streetinsider.com/FDA/UNITY+Biotechnology+%28UBX%29+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325/24739113.html Mon, 05 May 2025 08:01:55 -0400 UBX http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Press+Releases/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html <p align="center"><em>UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population </em></p> <p align="center"><em>UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients) </em></p> <p align="center"><em>Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn</em></p> <p>SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, http://www.streetinsider.com/Globe+Newswire/UNITY+Biotechnology+Announces+Complete+36-Week+Results+from+the+ASPIRE+Phase+2b+Study+of+UBX1325+in+Diabetic+Macular+Edema+and+Provides+Corporate+Updates/24739076.html Mon, 05 May 2025 08:00:00 -0400 A.60012014 O.20032830 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+May+02/24739088.html si-local-file:///var/storage/secattach/20250505/24739088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+May+02/24739088.html Mon, 05 May 2025 08:00:00 -0400 O.26574658 UBX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+May+02/24739088.html si-local-file:///var/storage/secattach/20250505/24739088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Unity+Biotechnology%2C++++++For%3A+May+02/24739088.html Mon, 05 May 2025 08:00:00 -0400 O.26574658 UBX